重庆太极实业（集团）股份有限公司 关于对国药集团财务有限公司的风险持续 评估报告 为了持续规范重庆太极实业（集团）股份有限公司及子公司（以 下简称"公司"）与国药集团财务有限公司（以下简称"财务公司"） 的关联交易，根据《上海证券交易所上市公司自律监管指引第5号— 交易与关联交易》等相关法律、法规和规范性文件的规定，通过查验 财务公司《金融许可证》《企业法人营业执照》等证件资料，并审阅 了财务公司截至2025年6月30日的财务报告以及风险指标等必要信息， 对财务公司的经营资质、业务和风险状况进行了评估，具体情况报告 如下： 一、国药财务公司基本情况 注册地址：北京市海淀区知春路20号中国医药大厦7层 法定代表人：王鹏 金融许可证机构编码：L0145H211000001 统一社会信用代码：9111000071783212X7 目前国药财务公司注册资本金为人民币220,000万元，股权结构 如下表所示： | 序号 | 股东名称 | 出资额（万元） | 持股比例 | | --- | --- | --- | --- | | 1 | 中国医药集团有限公司 | 116,105 | 52.7750% | | 2 | 中国生 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-062 重庆太极实业（集团）股份有限公司 第十届董事会第三十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）第十届 董事会第三十一次会议于 2025 年 8 月 11 日以邮件方式发出书面通知， 于 2025 年 8 月 20 日以现场及视频方式召开。本次会议由董事长俞敏 先生主持，会议应到董事 13 人，实到董事 13 人，公司高级管理人员 列席了会议。本次会议的召集、召开程序符合《公司法》和《公司章 程》的有关规定，会议合法有效。会议审议并通过了如下议案： 1 果：通过。 三、关于公开挂牌出售公司闲置资产的议案（具体内容详见公司 披露的《关于公开挂牌出售闲置房产的公告》；公告编号：2025-064） 一、公司《2025 年半年度报告及半年度报告摘要》（具体内容 详见公司在上海证券交易所网站（www.sse.com.cn）披露的《2025 半年度报告及半年度报告摘要》） 同意公司将名下位于成都 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-066 重庆太极实业（集团）股份有限公司 关于以集中竞价交易方式回购股份的回购 报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法 承担法律责任。 重要内容提示： ●回购股份金额：不低于 8,000 万元（含）且不超过 12,000 万元 （含）。 ●回购股份方式：以集中竞价交易方式回购。 ●回购股份期限：自公司股东大会审议通过回购方案之日起 12 个 月内。 ●相关股东是否存在减持计划：否 ●相关风险提示：1.本次回购方案需通知债权人，可能存在公司 无法满足债权人清偿债务或提供担保进而导致回购方案难以实施的风 险；2.本次回购股份存在回购期限内公司股票价格持续超出回购方案 披露的价格上限，导致本次回购股份方案无法实施的风险。3.可能存 在回购股份所需资金未能到位，导致本次回购方案无法实施的风险；4. 若发生对公司股票交易价格产生重大影响的重大事项，或公司生产经 1 营、财务情况、外部客观情况发生重大变化，或其他导致本次回购股 份方案终止的事项发生，则存在回购方案无法顺 ...

Financial Performance - The company's operating revenue for the first half of 2025 was approximately CNY 5.66 billion, a decrease of 27.63% compared to CNY 7.82 billion in the same period last year[25]. - The total profit for the reporting period was CNY 197.87 million, down 66.82% from CNY 596.43 million year-on-year[25]. - The net profit attributable to shareholders was CNY 138.80 million, representing a decline of 71.94% from CNY 494.61 million in the previous year[25]. - The basic earnings per share decreased to CNY 0.25, down 71.91% from CNY 0.89 in the same period last year[24]. - The weighted average return on net assets was 3.90%, a decrease of 8.88 percentage points compared to 12.78% in the previous year[24]. - The net cash flow from operating activities was CNY 114.82 million, a significant improvement from a negative CNY 357.24 million in the previous year[25]. - The total assets at the end of the reporting period were CNY 14.22 billion, an increase of 1.16% from CNY 14.06 billion at the end of the previous year[25]. - The net assets attributable to shareholders increased by 3.98% to CNY 3.63 billion from CNY 3.49 billion at the end of the previous year[25]. Market and Industry Context - The pharmaceutical manufacturing industry achieved revenue of 1,227.5 billion yuan in the first half of 2025, a year-on-year decrease of 1.2%[39]. - The total profit for the pharmaceutical manufacturing industry was 176.7 billion yuan in the first half of 2025, down 2.8% year-on-year[39]. - The OTC market growth is slowing, with a shift towards digital transformation in the pharmaceutical distribution sector[39]. Company Strategy and Focus - The management indicated that the decline in performance was primarily due to policy changes and the ongoing digestion of social inventory for certain products[24]. - The company aims to enhance product core competitiveness and strengthen the industrial marketing system in the second half of the year[44]. - The company is focusing on the construction of GAP bases for five major Chinese medicinal materials, with a static inventory capacity reaching 13,000 tons[49]. - The company is advancing its digital transformation by launching over 20 AI application scenarios and implementing various management systems[51]. - The company is committed to optimizing its financial management and establishing a comprehensive cost accounting system covering sales, production, management, and research[79]. Research and Development - The company has applied for 16 patents in the first half of 2025, with 7 being invention patents[32]. - The company has successfully developed over 40 new drugs and holds 336 national patents, showcasing its strong research capabilities[58]. - Research and development expenses increased by 18.12% to approximately ¥137.42 million, reflecting the company's commitment to innovation[60]. Risk Management - The company has faced market and policy risks, including frequent adjustments in the pharmaceutical sector, which could impact product accessibility and competitiveness due to potential changes in the medical insurance directory[73]. - The company is implementing measures to mitigate risks, including establishing a dedicated policy research team to track regulatory changes and enhance cost control and pricing negotiation strategies[74]. - Quality risk is heightened due to stricter regulations, necessitating the establishment of a comprehensive quality traceability system across all production and sales stages[75]. Financial Management - The company has a maximum deposit limit of CNY 500 million with its financial subsidiary, with a deposit interest rate range of 0.25%-0.90%[100]. - The company has a loan limit of CNY 1 billion with its financial subsidiary, with a loan interest rate range of 2.11%-2.4%[103]. - The company provided guarantees totaling CNY 73.60 million, which accounts for 1.95% of the company's net assets[108]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 54,088[112]. - The largest shareholder, Taiji Group Co., Ltd., holds 27.62% of the shares, totaling 153,812,354 shares[114]. - The company did not distribute profits or increase capital reserves during the reporting period[9]. Inventory and Assets - Accounts receivable increased by 36.26% to approximately ¥2.85 billion, representing 20.02% of total assets[63]. - The total current assets as of June 30, 2025, amounted to RMB 6,830,711,739.35, an increase from RMB 6,704,246,213.35 as of December 31, 2024, reflecting a growth of approximately 1.88%[121]. - Inventory decreased to RMB 2,241,033,500.12 from RMB 2,726,720,129.18, indicating a reduction of about 17.83%[121]. Compliance and Governance - The company has been recognized with an A rating in the 2024 ESG report by WIND, reflecting its commitment to environmental, social, and governance standards[82]. - The company is included in the list of enterprises required to disclose environmental information, with three subsidiaries listed[91]. - The company actively promotes the integration of the traditional Chinese medicine industry chain, focusing on rural revitalization and poverty alleviation efforts[92].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、账户被冻结情况 重庆太极实业（集团）股份有限公司（以下简称：公司）财务人 员查询银行账户时获悉公司及子公司西南药业股份有限公司（以下简 称：西南药业）部分银行账户被冻结，具体情况如下： 证券代码：600129 证券简称：太极集团 公告编号：2025-067 重庆太极实业（集团）股份有限公司 关于公司及子公司部分银行账户被冻结的 公告 公司将依法主张自身合法权益，采取相关法律措施，同时积极与 相关各方进行沟通，尽快解决上述纠纷事项，消除上述银行账户资金 被冻结的风险，使被冻结银行账户尽快恢复正常。 三、对公司的影响及风险提示 （一）截至本公告披露日，上述银行账户本次被申请冻结金额合 计 6,292.12 万元，占公司最近一期经审计净资产的 1.73%；占公司 最近一期经审计货币资金的 7.75%，除上述披露的银行账户冻结情形 外，公司尚有其他银行账户可正常使用，上述银行账户被冻结暂未对 公司的正常运行、经营管理造成重大不利影响。 （二）鉴于本次银行账户部分资金被冻结所涉及 ...

证券代码：600129 证券简称：太极集团 公告编号：2025-064 重庆太极实业（集团）股份有限公司 关于公开挂牌出售闲置房产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 重庆太极实业（集团）股份有限公司（以下简称：公司）拟将公 司名下位于成都市成华区建设路 52 号房产以公开挂牌的方式在产权 交易所出售，首次挂牌价格不低于上述房产的评估值共计 3,913.60 万元，最终转让价格以产权交易所挂牌成交结果为准。 本次交易将通过公开挂牌方式转让，交易对方存在不确定性，尚 不确定是否构成关联交易。 本次交易不构成《上市公司重大资产重组管理办法》规定的重大 资产重组。 本次交易事项已经公司第十届董事会第三十一次会议审议通过， 根据《上海证券交易所股票上市规则》，本次交易在董事会审批权限 范围内，无需提交公司股东大会审议。 风险提示：本次交易将通过公开挂牌的方式转让，交易能否达成 及最终成交价格均存在不确定性。公司将密切关注本次交易的进展情 况，严格按照《上海证券交易所股票上市规则》等法律法规的规定， ...

太极集团公告，2025年上半年营业收入56.58亿元，同比下降27.63%。净利润1.39亿元，同比下降 71.94%。公司2025年半年度不进行利润分配，也不进行资本公积金转增股本。 ...

人民财讯8月21日电，太极集团（600129）8月21日晚间披露2025年半年度报告，上半年实现营业收入 56.58亿元，同比下降27.63%；归母净利润1.39亿元，同比下降71.94%；基本每股收益0.25元。净利润同 比下降主要受相关政策以及部分产品社会库存持续消化等因素影响，营业收入较上年同期减少。 ...

Group 1 - The core viewpoint of the article highlights the decline in the production of traditional Chinese medicine (TCM) in China, with a projected decrease in output and significant year-on-year reductions [1][3] - According to data from the National Bureau of Statistics, the production of TCM in China is expected to be 156,000 tons by June 2025, representing a year-on-year decrease of 6.6% [1] - In the first half of 2025, the cumulative production of TCM in China reached 875,000 tons, showing a cumulative decline of 13% [1] Group 2 - The article lists several publicly listed companies in the TCM sector, including Yunnan Baiyao, Tongrentang, and others, indicating the key players in the industry [1] - The report referenced is the "2025-2031 China Traditional Chinese Medicine Industry Development Situation Analysis and Industry Prospect Planning Report" published by Zhiyan Consulting, which provides insights into the future of the TCM industry [1][2]

Industry Overview - The number of registered companies in China's Ejiao industry has shown a growth trend, with over 600 companies registered as of June 2025, and nearly 200 new companies added between 2016 and 2020 [1][3] - The production of Ejiao blocks in China is projected to increase, with an estimated production of 4,379 tons in 2024 [3] Supply Situation - The sales-to-production ratio of Dong'e Ejiao has been declining over the past three years, dropping from 100.9% in 2022 to 97.9% in 2024, indicating increased inventory pressure [5] Demand Scale - The market size of the Ejiao industry in China is expected to reach approximately 29.1 billion yuan in 2024, driven by rising disposable income and increased health awareness among consumers [7] Price Trends - The prices of Ejiao products from major brands like Dong'e Ejiao and Fupai Ejiao have remained stable, with Dong'e Ejiao priced at 2,700 yuan per kilogram and Fupai Ejiao at approximately 1,260 yuan per kilogram [9]